Autres langues LifeMD, Inc.

Actions

LFMD

US53216B1044

Equipement et technologie médicale avancés

Marché Fermé - Nasdaq 22:00:00 04/09/2026			Varia. 5j.	Varia. 1 janv.
3,080 ^USD	+0,98%		-0,32%	-9,68%

06/08	LifeMD, Inc. : Opinion positive de B. Riley	ZM
05/08	Transcript : LifeMD, Inc., Q2 2026 Earnings Call, Aug 05, 2026

Autres langues

05/08	LifeMD Reports Second Quarter 2026 Results
05/08	LifeMD, Inc. Revises Earnings Guidance for the Full Year of 2026
05/08	LifeMD, Inc. Provides Earnings Guidance for the Third Quarter and Fourth Quarter of 2026
05/08	LifeMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
24/07	LifeMD to Report Second Quarter 2026 Financial Results on August 5
24/06	Best GLP-1 Medical Weight Loss Clinics in 2026 \| Good Life Health
23/06	LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
22/06	LifeMD, Inc. And Antares Pharma, Inc. Launch Direct-To-Patient Self-Pay Program For XYOSTED (Testosterone Enanthate) Injection
22/06	LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
01/06	LifeMD, Inc. Announces Appointment of Umesh Sripad to Chief Technology Officer, Effective June 01, 2026
01/06	LifeMD Names Umesh Sripad as Chief Technology Officer
01/06	LifeMD Appoints Umesh Sripad as Chief Technology Officer
22/05	Bone Health in Women
18/05	LifeMD to Participate in Upcoming Investor Conferences
15/05	LifeMD to Participate in Upcoming Investor Conferences
06/05	LifeMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
06/05	LifeMD Reports First Quarter 2026 Results
06/05	LifeMD, Inc. Provides Earnings Guidance for the Second Quarter and Affirms Earnings Guidance for the Full Year 2026
27/04	LifeMD to Report First Quarter 2026 Financial Results on May 6
20/04	Health Care Down Ahead of Earnings -- Health Care Roundup
13/04	LifeMD(R) Now Offering Eli Lilly and Company's Foundayo (orforglipron), a New GLP-1 Pill for Weight Management
10/04	LifeMD Now Offers Eli Lilly's Foundayo to Eligible Patients Through its Weight Management Program
10/04	LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
10/04	Lifemd Inc Announces Foundayo Orforglipron Oral Glp-1 Pill for Weight Management
01/04	LifeMD Offers Novo Nordisk's Industry-First Wegovy Telehealth Subscription Program